553-08-2
Chemical Structure
Thonzonium bromide
- CAS No.: 553-08-2
- Formula:C32H55BrN4O
- Molecular Weight:591.71
IUPAC Name: N-(2-((4-methoxybenzyl)(pyrimidin-2-yl)amino)ethyl)-N,N-dimethylhexadecan-1-aminium bromide
InChIKey: WBWDWFZTSDZAIG-UHFFFAOYSA-M
SMILES: CCCCCCCCCCCCCCCC[N+](C)(CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2)C.[Br-]
Biological Activity: Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Thonzonium bromide | 99.81% | Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Thonzonium bromide (Standard) | ≥98% | Thonzonium (bromide) (Standard) is the analytical standard of Thonzonium (bromide). This product is intended for research and analytical applications. Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhu X, et al. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016;104:118-130. [Content Brief]
- [2]. Chan CY, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J Biol Chem. 2012;287(13):10236-10250. [Content Brief]
- [3]. Sims KR, et al. Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery. Nanoscale. 2018;11(1):219-236. [Content Brief]
